Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma

Ophthalmology

Volumn 110, Issue 6, 2003, Pages 1241-1244

  Mason III, John O ^a   Fischer, David H ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; METHOTREXATE;

ADULT; AGED; ARTICLE; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTRAOCULAR LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 0037983788     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00268-9     Document Type: Article

References (20)

1. Paulus W. Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 1999;43:203-8.
2. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999;43:199-201.
3. Char DH, Ljung BM, Miller T, Phillips T. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 1988;95:625-30.
4. Merchant A, Foster CS. Primary intraocular lymphoma. Int Ophthalmol Clin 1977;37:101-15.
5. DeAngelis LM. Current management of primary central nervous system lymphoma. Oncol 1995;9:63,71; discussion 71,75-6,78.
6. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71.
7. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
8. Rothova A, Ooijman F, Kerkhoff F, et al. Uveitis masquerade syndromes. Ophthalmology 2001;108:386-99.
9. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer 1993;72:843-9.
10. Ciulla TA, Pesavento RD, Yoo S. Subretinal aspiration biopsy of ocular lymphoma. Am J Ophthalmol 1997;123:420-2.
11. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999;43:241-7.
12. Balis FM, Poplack DG. Central nervous system pharmacology of anti-leukemic drugs. Am J Pediatric Hematol Oncol 1989; 11:74-86.
13. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculosisternal perfusion. J Pharmacol Exp Ther 1975;195:73-83.
14. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999;26:346-56.
15. Strauchen JA, Dalton J, Friedman AH. Chemotherapy in the management of intraocular lymphoma. Cancer 1989;63:1918-21.
16. Baumann MA, Ritch PS, Hande KR, et al. Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 1986;57:1273-5.
17. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-6.
18. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurol 1996;46:435-9.
19. Jacobs SA, Bleyer WA, Chabner BA, Johns DG. Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1975;1:465-6.
20. Simmons EO, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 1991;67:2062-5.